美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

291.47

-4.9900-1.68%

盘后：291.470.00000.00%16:39 EDT

成交量：17.12万

成交额：4,989.66万

市值：345.83亿

市盈率：-78.71

高：293.17

开：289.73

低：287.00

收：296.46

数据加载中...

总览公司新闻公告

百济神州7月25日成交额为4989.78万美元

国产创新药PD-1与VEGF靶向药物亮相世界肺癌大会

东富龙助力百济神州三期工厂：护航百泽安生产，打造PD-1的“智造”基石

每周医刻｜国家医保局：集采中选不再简单以最低报价作为参考；重磅！迈瑞医疗拟赴港IPO

百济神州7月24日成交额为7049.65万美元

百济神州-U股价微跌0.19% 二季度获201家基金重仓

新事丨罗氏终止TIGIT全部三期临床

当3000亿资金涌向18A新股

第十一批国家药品集采深度解析

强化源头创新，百济神州北京昌平新研发创新中心启用

北京日报客户端

百济神州北京昌平新研发创新中心启用

断腕十年：722事件如何重塑中国医药产业基因？

CPHI制药在线

百济潜在 BIC 蛋白降解剂获批新临床

Insight数据库

百济神州7月22日成交额为7851.02万美元

百济神州、科伦博泰等8家药企大单品剖析

2025年《财富》中国500强发布！17家药企上榜

券商资管系公募，排名来了！

中国基金报

科创第五套上市公司市值表现如何？解构标准重启隐含的价值导向

深耕的智慧：喧嚣时代的生物医药“长期主义”

建国路128号

百济神州终止 DGKζ 抑制剂临床开发

Insight数据库

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":291.47,"timestamp":1753473600000,"preClose":296.46,"halted":0,"volume":171194,"hourTrading":{"tag":"盘后","latestPrice":291.47,"preClose":291.47,"latestTime":"16:39 EDT","volume":1979,"amount":576814.86,"timestamp":1753475983218},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"休市中","change":-4.99,"latestTime":"07-25 16:00:00 EDT","open":289.73,"high":293.165,"low":287,"amount":49896623.98421,"amplitude":0.020795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":296.46,"preHourTrading":{"tag":"盘前","latestPrice":291,"preClose":296.46,"latestTime":"09:28 EDT","volume":38,"amount":11165.538480000001,"timestamp":1753450080032},"postHourTrading":{"tag":"盘后","latestPrice":291.47,"preClose":291.47,"latestTime":"16:39 EDT","volume":1979,"amount":576814.86,"timestamp":1753475983218},"volumeRatio":0.40463067027862526,"impliedVol":0.4268,"impliedVolPercentile":0.4714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.40463067027862526,"shares":118650120,"dividePrice":0,"high":293.165,"amplitude":0.020795,"preClose":296.46,"low":287,"week52Low":155.75,"pbRate":"9.88","psRate":"8.28","week52High":300,"institutionHeld":0,"latestPrice":291.47,"eps":-3.70325,"divideRate":0,"volume":171194,"delay":0,"ttmEps":-3.70325,"open":289.73,"prevYearClose":184.71,"prevWeekClose":294.55,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":294.55,"twentyDayClose":254.49,"sixtyDayClose":249.77,"earningDate":1754409600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554405713","title":"百济神州7月25日成交额为4989.78万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554405713","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554405713?lang=zh_cn&edition=fundamental","pubTime":"2025-07-26 12:49","pubTimestamp":1753505370,"startTime":"0","endTime":"0","summary":"美东时间2025年7月25日，百济神州成交额为4989.78万美元，成交额较昨日减少29.22%，当日成交量为17.12万股。百济神州于2025年7月25日跌1.68%，报291.47美元，该股过去5个交易日跌1.05%，年初至今涨57.8%，过去60日涨16.7%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726124937a4644c12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726124937a4644c12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4139"],"gpt_icon":0},{"id":"2554902967","title":"国产创新药PD-1与VEGF靶向药物亮相世界肺癌大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2554902967","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554902967?lang=zh_cn&edition=fundamental","pubTime":"2025-07-26 09:13","pubTimestamp":1753492383,"startTime":"0","endTime":"0","summary":"国内企业多项研究成果入选本次大会。迪哲医药表示，公司自主研发的新型肺癌靶向药舒沃哲和高选择性JAK1抑制剂高瑞哲在非小细胞肺癌中的多项最新研究成果将在今年的WCLC上公布。上述研究中包括多款国产创新药。除了PD-1以外，针对VEGF的靶向药物也频繁出现在摘要报告中。该机构指出，PD-1/VEGF双抗药物有望逐步替代PD-1单抗市场，预计至2028年全球市场规模近700亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726092213971f7098&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726092213971f7098&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688180","06160","ONC","02696","BK0239","01877","688192","688235"],"gpt_icon":0},{"id":"2554036757","title":"东富龙助力百济神州三期工厂：护航百泽安生产，打造PD-1的“智造”基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2554036757","media":"东富龙","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554036757?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:01","pubTimestamp":1753430479,"startTime":"0","endTime":"0","summary":"往期回顾REVIEW通化东宝与东富龙集团达成战略合作 共谋糖尿病治疗领域新发展东富龙荣膺2025年度生物制造产业奖项“生物制造·中试产线最佳合作伙伴”殊荣！东富龙秉承“天道酬勤”核心价值观，坚守“专业技术服务于生物医药”的使命，以“系统化、国际化、数智化”的发展战略，不断前行。东富龙拥有四个核心事业部：工艺事业部、制剂装备事业部、工程事业部、食品工程事业部。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725162921a462ed1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725162921a462ed1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD","LU1169589451.USD","ONC","BK4526","BK4139","BK4023","06160","LU1169590202.USD"],"gpt_icon":0},{"id":"2554768252","title":"每周医刻｜国家医保局：集采中选不再简单以最低报价作为参考；重磅！迈瑞医疗拟赴港IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2554768252","media":"财健道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554768252?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 15:40","pubTimestamp":1753429227,"startTime":"0","endTime":"0","summary":"政策1国家医保局：集采中选不再简单以最低报价作为参考7月24日，国家医保局在国新办举行的发布会上明确提到：集采不再以简单的最低价作为参考，报出最低价的企业要公开说明报价的合理性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725160943a462e18f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725160943a462e18f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1222","LU2328871848.SGD","09997","688235","09996","BK1574","06978","BK1161","ONC","688520","LU2488822045.USD","BK1100","01801","BK1515","00512","GSK","BK1589","BK1583","06160","09939"],"gpt_icon":0},{"id":"2554753199","title":"百济神州7月24日成交额为7049.65万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554753199","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554753199?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 12:40","pubTimestamp":1753418414,"startTime":"0","endTime":"0","summary":"美东时间2025年7月24日，百济神州成交额为7049.65万美元，成交额较昨日减少40.04%，当日成交量为23.84万股。百济神州于2025年7月24日涨0.55%，报296.46美元，该股过去5个交易日涨2.1%，年初至今涨60.5%，过去60日涨18.84%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725124016a46289c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725124016a46289c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2554877817","title":"百济神州-U股价微跌0.19% 二季度获201家基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877817","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554877817?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 02:33","pubTimestamp":1753382029,"startTime":"0","endTime":"0","summary":"截至2025年7月24日收盘，百济神州-U股价报237.68元，较前一交易日下跌0.45元，跌幅0.19%。当日成交量为21877手，成交金额达5.20亿元。百济神州-U属于医药生物行业，是一家专注于创新药物研发的生物科技企业。公司主要从事肿瘤、免疫肿瘤等领域的创新药物研发、生产和商业化。数据显示，2025年二季度末共有201家基金重仓持有百济神州-U，合计持股3850.52万股，占流通股比例达33.47%。在科创板公司中，百济神州-U的基金持股比例排名第二。7月24日，百济神州-U主力资金净流出453.23万元，占流通市值比例为0.02%。风险提示：投资有风险，入市需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725023955971c9964&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725023955971c9964&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK0239","ONC"],"gpt_icon":0},{"id":"2553078322","title":"新事丨罗氏终止TIGIT全部三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553078322","media":"健识局","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553078322?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 20:30","pubTimestamp":1753360205,"startTime":"0","endTime":"0","summary":"在最新的管线中，PD-1联合TIGIT治疗非小细胞肺癌、肝癌的三期临床均已终止。这意味着罗氏针对TIGIT进行的三期临床全部终止。TIGIT靶点的价值是罗氏在2009年最先发现的。当时，罗氏的TIGIT+PD-L1联合疗法的效果曾一鸣惊人，一度被认为是PD-1之后的免疫新星。全球范围内，这几年TIGIT单抗预期快速变化：默沙东、罗氏等药企都已经历多次失败，留给TIGIT靶点成功的希望相当渺茫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","LU1064131003.USD","LU2328871848.SGD","LU1328615791.USD","LU1997245177.USD","BK0188","600276","MRK","688177","LU1969619763.USD","BK0183","LU2495084118.USD","06160","01276","LU1064130708.USD","BK0012","LU1997244956.HKD","BK0060","LU1997245094.SGD","LU1655091616.SGD","LU2148510915.USD","ONC","688235","688266","LU2488822045.USD","BK0028","LU0405327148.USD","BK0239","LU0405327494.USD","BK0196"],"gpt_icon":1},{"id":"2553917788","title":"当3000亿资金涌向18A新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553917788","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553917788?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 19:58","pubTimestamp":1753358280,"startTime":"0","endTime":"0","summary":"7月22日维立志博完成认购，数据显示其融资申购金额飙至惊人的3300亿港元，散户认购倍数超3000倍。目前其暗盘交易显示，股价已经大涨超过90%，总市值超130亿港元。/ 02 /成功样本港股18A新股受追捧的盛况，并非始于维立志博。二级市场融资渠道已显著畅通：截至目前，已有10家药企完成IPO，募资总额逼近200亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203654a46157fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203654a46157fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SBHMY","09926","AAPG","01530","LEGN","ONC","LU1064131003.USD","01952","BK0239","09606","01228","06160","01167","LU2488822045.USD","688235","LU1064130708.USD","LU2148510915.USD","688506","688331","02616","09995","01177","06855"],"gpt_icon":0},{"id":"2553202959","title":"第十一批国家药品集采深度解析","url":"https://stock-news.laohu8.com/highlight/detail?id=2553202959","media":"华安ETF","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553202959?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 17:40","pubTimestamp":1753350034,"startTime":"0","endTime":"0","summary":"事件2025年7月15日，国家组织药品联合采购办公室正式发布《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》。这些变化体现了\"新药不集采、集采非新药\"的基本原则，为创新药划出了明确的政策安全边界。前十批药品集采中，医疗机构只能按药品通用名报量，无法反映临床用药的品牌倾向性。创新药企业则受益于“新药不集采”原则，医保谈判药品在协议期内免于集采，保障了合理的利润空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724184925a6bf8959&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724184925a6bf8959&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","600276","688235","BK0239","01276"],"gpt_icon":0},{"id":"2553248310","title":"强化源头创新，百济神州北京昌平新研发创新中心启用","url":"https://stock-news.laohu8.com/highlight/detail?id=2553248310","media":"北京日报客户端","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553248310?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 20:15","pubTimestamp":1753272900,"startTime":"0","endTime":"0","summary":"7月23日，创新药企百济神州宣布，正式启用北京昌平研发创新中心的扩建新楼。百济神州联合创始人、董事长兼首席执行官欧雷强表示，得益于百济神州北京昌平研发创新中心，百悦泽和百泽安等具有里程碑意义的药物才能为无数癌症患者带来实实在在的帮助。据悉，自首款自主创新药物泽布替尼上市以来，百济神州自主研发的产品已惠及全球超过75个市场的180多万名患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507232025299719d8c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507232025299719d8c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2553321729","title":"百济神州北京昌平新研发创新中心启用","url":"https://stock-news.laohu8.com/highlight/detail?id=2553321729","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553321729?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 19:34","pubTimestamp":1753270463,"startTime":"0","endTime":"0","summary":"北京昌平研发创新中心是百济神州科学发现的重要策源地，也是最核心的研发中心之一。随着约3.7万平方米的新大楼启用，北京昌平研发创新中心总建筑面积达到约4.8万平方米，可容纳逾1300名员工在此工作。记者了解到，北京昌平研发创新中心具备从化学药和生物药的早期研发，到工艺制备及转化医学等多项综合研发功能，是百济神州临床前药物研发的核心枢纽。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723193433954e9e83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723193433954e9e83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK1500","LU0307460666.USD","LU1969619763.USD","BK1161","LU0588546209.SGD","BK1583","BK1588","LU2328871848.SGD","ONC"],"gpt_icon":0},{"id":"2553210630","title":"断腕十年：722事件如何重塑中国医药产业基因？","url":"https://stock-news.laohu8.com/highlight/detail?id=2553210630","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553210630?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 18:48","pubTimestamp":1753267701,"startTime":"0","endTime":"0","summary":"这种畸形的发展模式，使得整个行业陷入了低水平、无序的竞争状态，严重制约了中国医药产业的健康发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723195252a6bd5262&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723195252a6bd5262&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK0010","BK0028","600276","06160","BK0175","688235","BK0250","01276","688506","BK0188","600056","BK0239","BK0082","BK0185"],"gpt_icon":0},{"id":"2553216134","title":"百济潜在 BIC 蛋白降解剂获批新临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553216134","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553216134?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 16:28","pubTimestamp":1753259310,"startTime":"0","endTime":"0","summary":"7 月 23 日，CDE 官网显示，百济神州BGB-45035 片获批临床，用于治疗类风湿性关节炎。这是继特应性皮炎和结节性痒疹后，BGB-45035 获批的第三项临床。来源：CDE 官网BGB-45035 是一款靶向白细胞介素 1 受体相关激酶4的 蛋白降解剂。据百济介绍，BGB-45035 具有同类最佳潜力，在临床前模型中，相比 KT474，BGB-45035 可带来更快、更深度的 IRAK4 降解，且细胞因子抑制作用更强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723173827a6bd0654&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723173827a6bd0654&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688235","ONC","06160"],"gpt_icon":0},{"id":"2553296828","title":"百济神州7月22日成交额为7851.02万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553296828","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553296828?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 12:39","pubTimestamp":1753245594,"startTime":"0","endTime":"0","summary":"美东时间2025年7月22日，百济神州成交额为7851.02万美元，成交额较昨日减少15.61%，当日成交量为26.68万股。百济神州于2025年7月22日涨1.25%，报295.59美元，该股过去5个交易日涨9.6%，年初至今涨60.03%，过去60日涨15.39%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723124004a45df407&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723124004a45df407&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2553295650","title":"百济神州、科伦博泰等8家药企大单品剖析","url":"https://stock-news.laohu8.com/highlight/detail?id=2553295650","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553295650?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 12:01","pubTimestamp":1753243269,"startTime":"0","endTime":"0","summary":"以下将对百济神州、科伦博泰生物、康方生物、三生制药、百利天恒、信达生物、石药集团、一品红等企业的全球大单品进行深入剖析。2022 年 5 月，科伦博泰授予默沙东在大中华区以外所有地区开发、使用、制造及商业化该产品的独家权利。此药针对 NSCLC、乳腺癌、胃癌、妇科肿瘤等晚期实体瘤，展现了科伦博泰在 ADC 领域的研发实力。据悉，科伦博泰生物在 ADC、单抗、双抗、新靶点创新小分子药物等热点技术领域取得重大进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723120302954e05dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723120302954e05dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","688506","06990","ONC","BK4526","01093","BK4139","01530","06160","688235","09926"],"gpt_icon":0},{"id":"2553293804","title":"2025年《财富》中国500强发布！17家药企上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2553293804","media":"医药之梯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553293804?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 10:44","pubTimestamp":1753238677,"startTime":"0","endTime":"0","summary":"2025年《财富》中国500强榜发布，共有17家医药企业进入榜单。中国医药以营收914.857亿美元位居34名。医疗器械行业仅有迈瑞医疗这 1 家公司进入榜单。M司中国事业部负责人出走两名患者服用其药物死亡后，赛诺菲旗下公司宣布裁员500人突发！知名跨国药企高管因间谍罪在中国获刑3年半生物制药行业薪酬最高的20个人：最高8780万美元辉瑞传奇公关女高管离职！巨头药企年度裁员近900人！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723110943a6bc4156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723110943a6bc4156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600056","01276","02359","LU0588546209.SGD","LU1969619763.USD","603259","06160","LU0307460666.USD","BK1583","600276","600713","BK1500","ONC","688235","BK1161","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2553575942","title":"券商资管系公募，排名来了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2553575942","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553575942?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 00:06","pubTimestamp":1753200372,"startTime":"0","endTime":"0","summary":"头部券商资管公募管理规模普遍增长Wind数据显示，截至二季度末，共有4家券商资管机构的公募基金资产管理总规模超千亿元。此外，相比于今年一季度末，头部券商资管的公募管理规模普遍增长，东方红资产管理、华泰证券资管规模增长均超200亿元，招商证券资管规模增长33亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","06990","09969","01276","ONC","600276","688266","688192","688428","688443","BK0239"],"gpt_icon":0},{"id":"2553258739","title":"科创第五套上市公司市值表现如何？解构标准重启隐含的价值导向","url":"https://stock-news.laohu8.com/highlight/detail?id=2553258739","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553258739?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 19:21","pubTimestamp":1753183277,"startTime":"0","endTime":"0","summary":"按照第五套成功发行上市的20家企业全部为生物医药企业。本文将对采用科创第五套上市公司的市值表现、投资回报、经营情况和创新成果进行系统性梳理和分析，解构标准重启背后隐含的价值导向转变，并探讨标准重启带来的挑战。科创板第五套上市标准设计的核心，是承认并接纳了科技创新活动固有的高投入、长周期、高风险以及未来收益不确定性的特点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722192518a6babf05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722192518a6babf05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","01877","688331","BK0239","688180","688520","09969","688235","09995","159982","688428","688506","06160"],"gpt_icon":0},{"id":"2553238335","title":"深耕的智慧：喧嚣时代的生物医药“长期主义”","url":"https://stock-news.laohu8.com/highlight/detail?id=2553238335","media":"建国路128号","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553238335?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 15:11","pubTimestamp":1753168265,"startTime":"0","endTime":"0","summary":"而之所以在二级市场仍旧出圈，这背后折射出的，大概是其在喧嚣与浮躁中坚守“长期主义”的内在价值开始被市场重新发现和定价。放眼全球，丹麦的诺和诺德便是“长期主义”最完美的诠释者。图|诺和诺德股价走势图将目光转回国内，一批优秀的本土创新药企同样通过“长期主义”的践行，迎来了属于自己的高光时刻。最后，一家优秀的“长期主义”公司，其成功绝非依赖单一产品，而是一个整体性、连续性的系统。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722151356a6ba16f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722151356a6ba16f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4212","LU1093756168.USD","06160","688176","BK4599","688235","BK4007","06855","DDC","IE00BZ1G4Q59.USD","ONC","AAPG","IE00BKVL7J92.USD","BK4532","NVO","LU1093756325.SGD","BK4588","LU0154236417.USD","BK4585"],"gpt_icon":1},{"id":"2553282556","title":"百济神州终止 DGKζ 抑制剂临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2553282556","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553282556?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 13:34","pubTimestamp":1753162445,"startTime":"0","endTime":"0","summary":"近日，中国药物临床试验登记与信息公示平台显示，百济神州基于全面利益/风险评估，决定停止BGB-30813的临床开发，主动终止了一项正在进行的 I 期临床试验。截图来源：Insight 数据库Insight 数据库显示，在DGKζ 靶点竞争格局方面，全球有 6 款DGKζ 靶向药物进入临床阶段，来自 BMS、安斯泰来、百济神州、拜耳等，最高进展为临床 I/II 期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722142753a6b9fd0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722142753a6b9fd0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","06160","688235","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-24","current":-89.155571,"percent":0.00692,"low":-89.808695,"twenty":-48.008923,"median":-39.542215,"eighty":-23.186802,"high":-19.234246,"avg":-40.922145,"sd":19.149598,"marketCap":34981614879},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-24","current":-89.155571,"twenty":-48.008923,"median":-39.542215,"eighty":-23.186802,"marketCap":34981614879}],"updateTime":1753495463050}}}